

RESEARCH

Open Access



# Detecting gene–gene interactions from GWAS using diffusion kernel principal components

Andrew Walakira<sup>2\*</sup>, Junior Ocira<sup>1</sup>, Diane Duroux<sup>1</sup>, Ramouna Fouladi<sup>1</sup>, Miha Moškon<sup>3</sup>, Damjana Rozman<sup>2</sup> and Kristel Van Steen<sup>1,4</sup>

\*Correspondence:

adwalakira@gmail.com

<sup>2</sup> Centre for Functional Genomics and Bio-Chips, Institute for Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

Full list of author information is available at the end of the article

## Abstract

Genes and gene products do not function in isolation but as components of complex networks of macromolecules through physical or biochemical interactions. Dependencies of gene mutations on genetic background (i.e., epistasis) are believed to play a role in understanding molecular underpinnings of complex diseases such as inflammatory bowel disease (IBD). However, the process of identifying such interactions is complex due to for instance the curse of high dimensionality, dependencies in the data and non-linearity. Here, we propose a novel approach for robust and computationally efficient epistasis detection. We do so by first reducing dimensionality, per gene via diffusion kernel principal components (kpc). Subsequently, kpc gene summaries are used for downstream analysis including the construction of a gene-based epistasis network. We show that our approach is not only able to recover known IBD associated genes but also additional genes of interest linked to this difficult gastrointestinal disease.

**Keywords:** Inflammatory bowel disease, Diffusion kernel principal components, Bivariate synergy, Spike and slab priors, Gene epistasis network

## Introduction

It was Bateson [1] who first described epistasis as a biological process in which gene expression at one locus is suppressed by a gene at another locus. Several years later, Fisher came up with a non-equivalent definition of epistasis expressed in terms of deviations from a model of additive multiple effects regardless the scale (linear or logarithmic) [2]. In this work, we adopt the most commonly used reference to “epistasis”, as referring to any interaction between genes in which the contribution of one gene to a phenotype depends on genetic background. For more details about epistasis, what it means and does not mean, its analytic challenges and reproducibility concerns, we refer to [3] and more references in [4, 5]. Notably, epistasis research has evolved into a more general theory and application framework for the analysis of interactions across and between omics strata.



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Focusing on epistasis detection with data collected in genome-wide association studies (GWAS) [6–8], there are still numerous hurdles that when not taken care of properly may decrease our belief in the results and may complicate their interpretation [4]. Examples include computational and statistical issues related to the high-dimensionality of GWAS data and the corresponding number of multi-locus genotype combinations. Indeed, genome-wide Association Interaction Studies (GWAIS) involve hundreds of thousands of genetic markers (usually single nucleotide polymorphisms or SNPs) that need to be interrogated in pairs (or  $k$ -tuples). This makes correcting for multiple testing a daunting task. It is therefore not a surprise that the minority of epistasis detection methods aim for higher-order (more than  $k = 2$ ) interactions. One example is BHIT [9], a Bayesian High-order Interaction Toolkit for detecting epistatic interactions among SNPs.

In order to deal with problems associated with high dimensional modeling and testing, some researchers have applied filtering approaches to identify and only include in the final analysis, SNPs that are most probable to be involved in interactions. For example, Hemani and colleagues [10] applied a two stage analysis process. In the first stage, an experimental threshold was determined and used to remove SNPs with significant additive or dominant effects leaving a smaller set of unique SNP pairs for the second stage of the analysis. This is different from early days GWAIS practices where only GWAS hits were considered for subsequent epistasis checks. These different practices can be explained by considering the statistical hypotheses underlying the epistasis study: detecting interactions above and beyond main effects or detecting multi-locus joint effects (for more details see; Van Steen and Moore [4]). Also Pecanka et al. [11] applied a two stage strategy to be able to maximize the chances for epistasis signal detection with a reduced set. The reduction was achieved by applying a two-locus independence test in cases only prior to epistasis screening in cases and controls jointly. Several years before, two-locus information had been used by Calle et al. [12], who identified potentially interacting genes using a synergy measure in stage one and applied a prototype Model-Based Multifactor Dimensionality Reduction technique (MB-MDR) on the reduced set in stage 2.

Generally, these and similar methods have been successful in some cases but may also suffer from epistasis detection power loss. Furthermore, they embed a degree of subjectivity due to the choice of filtering or dimensionality reduction technique; different choices often leading to quite different results [13]. Thresholds need to be selected that may not be driven by biology but may need to be informed by sample size. For instance, GenEpi employs a feature extraction process to extract promising SNPs within each gene using randomized machine learning techniques. The randomization, even though increasing the computational burden, was introduced to reduce the number of false positives. However, small sample sizes may lead to over-fitting in GenEpi and require stringent feature selection thresholds at the expense of false negatives and unstable sets of positive signals in replication data [14].

In this work, we propose a novel epistasis detection analysis workflow that (1) takes GWAS SNP data as input, (2) develops gene-level summaries via diffusion kernels on graphs, and (3) uses these summaries as new units in epistasis (gene-gene) interaction

modelling. We illustrate the workflow using a Bayesian modelling framework and inflammatory bowel disease as case study.

## Materials and methods

### Data and data pre-processing

We used GWAS data on Inflammatory Bowel Disease (IBD) as part of the International IBD Consortium ([www.ibdgenetics.org](http://www.ibdgenetics.org)) and carried out quality control (QC) procedures as described in Ellinghaus et al. [15]. SNPs that were in Linkage Disequilibrium ( $r^2 > 0.75$ ) were pruned out. Only common variants (minor allele frequency  $> 5\%$ ) and those in Hardy-Weinberg equilibrium ( $p$  value  $> 0.001$ ) were considered. Then, we focused on SNPs potentially relevant for IBD. Specifically, FUMA software [16] was used to create eQTL SNP to gene mapping that mapped a SNP to its target gene when the association  $p$  value was significant in the colon. In addition, specific for the purposes of GWAIS, extra QC implementations were made as described in [17], building on recommendations from [18]. After these QC steps, the data comprised 66,280 individuals (32,622 cases and 33,658 controls) and 4398 SNPs.

Furthermore, the dichotomous phenotype (IBD or not) was corrected for population structure using the top 7 principal component analysis [19]. As in [15], the top 7 principal components were used to capture population structure. Trait correction for confounders is often done in epistasis research, especially when the targeted modeling framework does not accommodate the inclusion of fixed explanatory variables.


### Gene–gene interaction analysis workflow with diffusion kernel principal components

Our proposed epistasis detection strategy starts with SNP-to-gene annotation, which was carried out using the FUMA software [16] via eQTL mapping. This led to “gene files” with sets of SNPs. For those SNPs, missing genotypes were handled via  $k$ -nearest neighbour ( $k$ NN) imputation with  $k = 10$  using the *knn.impute* function in the bnstruct package [20]. The average missingness rate per SNP was 0.062%. Subsequent steps are explained in more detail in the following subsections. The entire analysis workflow is depicted in Fig. 1. Unless mentioned otherwise, all following data analyses are performed in the statistical software R, version 3.5.1 [21].

### Within-gene synergy

Bivariate synergy was used to construct SNP-based graphs within a gene and the resulting within-gene edge weights were used to obtain informed summaries of genes. We first discretized (binned) the population-structure corrected phenotype using  $k$ -means clustering based on the equal-width method implemented in the *discretize* function in the Infotheo package [22, 23]. Such binning strategies overcome difficulties in information gain computations for continuous phenotypes and have been shown to be useful for interaction detection between pairs of genetic markers [24]. Second, we calculated bivariate synergy *Syn* between a pair of SNPs as described by [25, 26]. In particular, given two SNPs  $A$  and  $B$ , and the phenotype  $C$ , *Syn* was calculated as follows:

$$Syn(A; B; C) = I(A, B; C) - [I(A; C) + I(B; C)] \quad (1)$$



where  $Syn(A; B; C)$  compares the joint contribution of SNPs  $A$  and  $B$  to the phenotype  $C$  with the additive contributions of the individual SNPs. The information gain  $I(A; C)$  about the phenotype  $C$  due to knowledge about SNP  $A$  and is defined as:

$$I(A; C) = H(C) - H(C|A) \tag{2}$$

$$I(A, B; C) = H(C) - H(C|A, B) \tag{3}$$

Here,  $H(C)$  denotes the entropy of  $C$  and  $H(C|A)$  (respectively  $H(C|A, B)$ ) refers to the conditional entropy of  $C$  given knowledge of SNP  $A$  (and  $B$ ). The entropy and conditional entropy of  $C$  are defined as:

$$H(C) = \sum_c p(c) \log \frac{1}{p(c)} \quad (4)$$

$$H(C|A) = \sum_{a,c} p(a, c) \log \frac{1}{p(c|a)} \quad (5)$$

with  $p(c)$  the probability that an individual has phenotype  $C = c$ . Likewise,  $p(c|a)$  is the probability of having phenotype  $C = c$  given genotype  $a$  for SNP  $A$ .

### Within-gene network analysis

For the construction of within-gene networks, SNPs were used as nodes and bivariate synergy between two SNPs provided edge weights. The “Maximum Relevance Minimum Redundancy” algorithm in the *minet* package in R [27] was used for meaningful node selection. In particular, the bivariate synergy matrices computed before were subjected to the *mrnet* function. The *mrnet* algorithm then computes a score that is used to rank the set of SNPs (vertices). For a particular target  $Y$  (each SNP is used as a target in turn), the algorithm starts by selecting the SNP  $S = X_i$  with the highest synergy with  $Y$ . Then SNP  $X_j$  with high synergy with  $Y$  and low synergy with  $X_i$  is selected. The algorithm updates  $S$ , the set of selected variables, by choosing the SNP:

$$X_j^{MRMR} = \operatorname{argmax}_{X_j \in V \setminus S} (u_j - r_j) \quad (6)$$

that maximises the score  $s_j = u_j - r_j$  where  $u_j$  is the relevance term  $u_j = I(X_j; Y)$  and  $r_j$  is the redundancy term:

$$r_j = \frac{1}{|S|} \sum_{X_k \in S} I(X_j; X_k) \quad (7)$$

The SNP network is then inferred by removing edges using an incremental search algorithm [27, 28]. This resulted in a reduced gene SNP set that was analysed with the *igraph* R package [29]. Several network properties were recorded for each within-gene network [30] including density and mean distance. A network’s density is defined as the ratio of actual versus potential connections. Mean distance is defined as the average of shortest paths between nodes. As a network connectivity measure, we chose transitivity i.e. capturing the tendency of network edges to form triangles via the ratio between the observed number of closed triplets and the maximum possible number of closed triplets in the network.

### Diffusion kernel principal components

Diffusion kernels were constructed over genotypes based on matrix exponentiation as described by [31, 32]. Using the adjacency matrix with bivariate synergies ( $Syn$ ) computed

in “Within-gene synergy” section, as off-diagonal weights and zeroes on the diagonal the Laplacian for each gene’s graph  $G$  was defined as:

$$L_{ij} = \begin{cases} W_{ij}, & \text{for } i \neq j \\ -\sum_{l=1}^n W_{il}, & \text{for } i = j. \end{cases}$$

Here,  $i$  refers to  $SNP_i$  and  $j$  to  $SNP_j$ , and  $W_{ij} = Syn(SNP_i; SNP_j; C)$ . With this Laplacian, the diffusion kernel is defined as

$$K_L = e^{\beta L} \quad (8)$$

with  $\beta$  is a parameter that regulates the degree of “diffusion”. Note that  $K_L$  is a matrix exponential. A  $\beta$  value of zero gives an identity diffusion kernel matrix. We generated 101 diffusion kernels  $K_L$  for  $\beta$  ranging from 0 and 10 (increments of 0.1) and took the average of the 101  $K_L$  to derive the final kernel matrix  $K_L$ .

Assuming  $G$  to be a  $n \times p$  genotype matrix, with  $n$  individuals and  $p$  SNPs allocated to the same gene, and  $G^T$  its transpose, the final gene-specific kernel of interest was defined as

$$K = GK_LG^T \quad (9)$$

Notably,  $K$  is a  $n \times n$  kernel matrix that has information about gene-level similarity between individuals, as well as joint effects of SNPs on the trait within each gene. We then centered each kernel matrix, performed an eigen decomposition using the RSpecTra package [33], and extracted the first principal component as a gene summary. The obtained gene constructs were considered as new units of gene-level epistasis analyses.

#### Detecting gene–gene interactions

An abundance of epistasis detection approaches with GWAS data exist. The vast majority of these approaches model or test for interactions at the SNP-level, assuming discrete data as input for their algorithms. In contrast, our proposed workflow assumes non-discrete input data i.e., one continuous variable per gene. The epistasis detection problem with GWAS data is consequently turned into a statistical problem that aims to at least capture, but preferentially detect, interactions between pairs of variables. Here, as an illustration, we used the Bayesian semi-parametric regression approach of [34] to infer non-linear gene-gene interactions, implemented in the NLinteraction R package. As gene explanatory variables for an individual  $i$ , we used the first kernel principal component  $\tilde{X}_{ij_1}$  for each gene  $j_1$  (see previous section). Genes and gene-gene interactions were selected on the basis of a so-called Posterior Inclusion Probability (PIP). This is a value for each effect of interest that indicates how likely it is to be included in the true model. Lesaffre and Lawson reported that PIP can “replace classical  $p$  values” [35]. See [36–38] for more information and application of PIP.

In particular, main effects and 2-way interaction effects were modelled as follows, exemplified for two genes  $j_1$  and  $j_2$ : The main effects of gene 1 ( $j_1$ ) were modelled as in Eq. (11).

$$f(X_{j_1}) = \tilde{X}_{j_1} \beta_{j_1} \quad (10)$$

and the interaction effect between gene 1 and gene 2 were modelled as in Eq. (12).

$$f(X_{j_1}, X_{j_2}) = \tilde{X}_{j_1} \beta_{j_1} + \tilde{X}_{j_2} \beta_{j_2} + \tilde{X}_{j_1} \tilde{X}_{j_2} \beta_{j_1 j_2} \quad (11)$$

with  $\tilde{X}_{j_1} = g_1(X_{j_1})$  and  $\tilde{X}_{j_2} = q_1(X_{j_2})$ , where  $g(\cdot)$  and  $q(\cdot)$  are natural basis functions of  $X_{j_1}$  and  $X_{j_2}$  respectively and  $\tilde{X}_{j_1 j_2} = g_1(X_{j_1})q_1(X_{j_2})$  the basis expansion of the interaction between  $X_{j_1}$  and  $X_{j_2}$ , as explained in [34].

The complete model formulation makes the following assumptions for the response  $Y_i$  for individual  $i$ ,  $i : 1 \dots n$ ,  $n$  the number of individuals:

$$Y_i \sim \text{Normal}(f(X_i, \sigma^2))$$

$$f(X_i) = \sum_{h=1}^k f^{(h)}(X_i) \quad (12)$$

$$f^{(h)}(X_i) = \sum_{j_1=1}^p \tilde{X}_{ij_1} \beta_{j_1}^{(h)} + \sum_{j_1=2}^p \sum_{j_2 \leq j_1} \tilde{X}_{ij_1 j_2} \beta_{j_1 j_2}^{(h)}$$

Here,  $p$  refers to the number of genes, and  $k$  is a number sufficiently large such that all exposure effects can be captured by the model.



At the core of Bayesian modelling lies choosing a prior distribution, here for  $\beta_j$  and  $\beta_{j_1 j_2}$  in order to enforce sparsity. For this analysis, we kept the default settings of the authors: spike and slab priors were used to shrink parameters to zero hereby reducing the dimensionality of the data. In particular:

$$P(\beta_S^{(h)} | \zeta) = \left( 1 - \prod_{j \in S} \zeta_{jh} \right) \delta_0 + \left( \prod_{j \in S} \zeta_{jh} \right) \psi(\beta_S^{(h)}) \quad (13)$$

where  $S$  is a subset of  $1, 2, \dots, p$  and  $P(\zeta_{jh}) = \tau_h^{\zeta_{jh}} (1 - \tau_h)^{1 - \zeta_{jh}} 1(A_h \not\subset A_m \forall m \text{ or } A_h = \{\})$  where  $A_h = \{j : \zeta_{jh} = 1\}$  and  $\zeta = \{\zeta_{jh}\}$ , a matrix of binary indicators of which genes and interactions are included in the  $h$ th function in the model. Spike was considered to be a point mass at zero i.e.  $P(\beta = 0) > 0$ , and slab,  $\psi(\cdot)$ , a multivariate distribution centered at  $\mathbf{0}$  with covariance  $\Sigma_\beta$  (estimated by empirical Bayes) as a diagonal matrix with  $\sigma^2 \sigma^2$  on the diagonals. Both  $\tau_h$  and  $\Sigma_\beta$  control the amount of shrinkage. In order to assess convergence, we kept track of  $\sigma^2$  as shown in the trace plot (see Additional file 3: Figure S3a).

### Gene-level epistasis visualisation and gene annotation

Genes with a marginal PIP greater than zero and unique genes involved in interactions with a PIP greater than zero were retained for network analyses. In particular, the unique sets of genes thus obtained were submitted to GeneMANIA to visualize and interpret inter-connectivity between identified genes [39]. Furthermore, unique genes involved in gene-gene interactions ( $PIP > 0$ ) were propagated over a inBio network [40]. The inBio network is a protein–protein interaction network that integrates different studies and interaction types into a single evidence based integrated score for each gene/protein pair. To decipher the roles of highlighted genes as well as their




involvement in IBD pathology, the gene annotation data base DAVID [41, 42] and DisGeNET [43, 44] were interrogated.

### Results

SNPs were physically mapped to respective genes yielding a total of 878 genes (“gene files”). These genes were spread across 22 chromosomes (no sex chromosomes). We successfully calculated kernels for 496 genes. The computation of kernels was restricted to genes with three or more SNPs mapped to the respective gene.

Figure 2a–c display the within-gene networks between SNPs that were annotated to *AHS2*, *NOTCH4* and *SLC22A4* specifically. These exemplifying genes were picked up by the adopted Bayesian modelling strategy (interaction  $PIP > 0$ ) and suggest that gene size (number of SNPs) was not the determining factor for epistasis detection. In general, within gene networks differed by genes (Fig. 3). Genes such as *PARK7*, *CD40*, *NUCKS1*, *MST1R* and *SLC22A4*, known to be associated with IBD (CD or UC) showed higher-end densities (Fig. 3). The number of SNPs mapped to a respective gene varied from 140 SNPs for the HLA-K gene to 2 SNPs for genes such as *ZNF7* and *TRPT1*. The majority of genes had less than 20 SNPs, distance-wise mapped to them (Fig. 4b). There was no





**Table 1** Second-order gene–gene interactions and their respective posterior inclusion probabilities (PIP)

| Gene 1           | Gene 2          | PIP    |
|------------------|-----------------|--------|
| <i>LINC01475</i> | <i>NIT1</i>     | 0.0263 |
| <i>JAZF1.AS1</i> | <i>TAP2</i>     | 0.0090 |
| <i>LIME1</i>     | <i>NICN1</i>    | 0.0075 |
| <i>LRRC56</i>    | <i>OTUD3</i>    | 0.0071 |
| <i>AHSA2</i>     | <i>NOTCH4</i>   | 0.0025 |
| <i>CNTFR</i>     | <i>EIF2S2P3</i> | 0.0025 |
| <i>MAP1LC3A</i>  | <i>RGS14</i>    | 0.0025 |
| <i>CDC37P1</i>   | <i>OIP5.AS1</i> | 0.0015 |
| <i>CDC37P1</i>   | <i>SLC22A4</i>  | 0.0005 |
| <i>OIP5.AS1</i>  | <i>SLC22A4</i>  | 0.0005 |
| <i>DR1</i>       | <i>MAP1LC3A</i> | 0.0003 |

obvious relationship between the number of SNPs per main effects gene ( $PIP > 0$ ) and the corresponding median synergies (Fig. 4a).

Genes with a marginal or interaction PIP greater than zero were used to construct interaction networks in GeneMANIA, searched on 7th December 2021. For Fig. 5, the search term was the list of all genes with PIP greater than 0 from the main effects model (see Additional file 2: Table S2). For Fig. 6, the search term was the unique set of genes whose interaction had a PIP greater than zero (Table 1). The objective was to retrieve novel connections between our own identified genes and other genes given known interaction information in curated databases.

Furthermore, we searched for external evidence for association of our selected genes with IBD, Crohn’s Disease (CD) or Ulcerative Colitis(UC) using DAVID and DisGeNET. Genes *SLC22A4*, *OTUD3*, *PARK7*, *NOTCH4*, *GPR35*, *DAP*, *UBA7*, *MST1*, *MST1R*, *CD40*, *TAP2*, *NICN1*, *RGS14*, *LINC01475*, *GBAP1*, *NUCKS1*, *HCG23*, *CCDC88B*, *HEART3*, and *ERAP2*, have been previously associated with IBD, CD or UC. Of the genes involved in 2-way interactions (Table 1), seven genes namely *LINC01475*, *TAP2*, *RGS14*, *OTUD3*, *SLC22A4*, *NICN1* and *NOTCH4* have already been associated with IBD, CD or UC. From the network (Fig. 6), genes *MAP1LC3A*, *UBR4* and *CNTFR* are attractive for further



investigation. Their degree (number of connected edges) and nature of connections in which they are involved warrant in-depth investigation of their potential roles in IBD pathology. For instance, *MAP1LC3A* has degree 5, while *CNTFR* has a degree of 8, with the both genes being central to two clusters of genes in the network. Also, *MAP1LC3A* has been implicated in related diseases e.g. in cancers of the gastro intestinal system [45, 46]. Gene *CNTFR* has been implicated in rheumatoid arthritis, a chronic inflammatory disorder [47], and *UBR4* in anorectal malformations and stomach cancer [48, 49].

## Discussion

High-throughput technologies have facilitated multi-omics profiling of individuals. Since the first complete sequence of the human genome, several genome-wide association studies comparing cases and controls have emerged. These studies have been successful to obtain a better understanding of biological underpinnings of complex diseases such as Inflammatory Bowel Disease (IBD), a highly prevalent disease that is characterized by chronic inflammation of the gastrointestinal tract [50]. According to DisGeNet and the NHGRI-EBI GWAS Catalog, over 170 genes are reported to be associated with inflammatory bowel diseases. Despite the appreciable number of GWAS findings, only a few of these have shown immediate impact in clinical practice. This is not surprising. GWAS only offer one view of the complexity of an individual's health. Interactome analyses offer another view. The interactome refers to the entire complement of interactions between DNA, RNA, proteins and metabolites within a cell. In this work, we have focused on one particular type of interactions, namely "DNA-DNA" interactions, using genetic markers from GWAS, in particular SNPs, as vehicles. The context is thus genome-wide association interaction studies (GWAIS), building on GWAS and aiming to identify interacting SNPs in relation to a phenotype of interest.

Several reviews exist on GWAIS. These focus on the definition of epistasis [5, 6], on the vast amount of analytic approaches that exist [3, 6, 51] on the difference between capturing and detecting epistasis [52] or on how to adapt the analysis workflow to increase our belief in statistical interactions with SNPs and to maximize translation opportunities [4], amongst others. The latter reference highlights the many issues that still exist for GWAIS analyses, including replication issues at the SNP level or interference by linkage disequilibrium patterns in the data. Gene-level epistasis analysis may be better suited towards increased interpretability and replication across studies. Also, they may be the road to travel by for epistasis detection with GWAS SNP data when millions of SNPs need to be screened. In practice, such enormous datasets require adopting filtering or dimensionality reduction approaches. These may involve the incorporation of prior biological knowledge (for instance, restricting the search space to SNP-level interactions that involve known gene-level biological interactions) [53], or a transformation of SNP-level to gene-level analysis via tissue-specific SNP induced estimates of gene expression [54]. To our knowledge, one of the first gene-level epistasis analysis methods, starting from GWAS SNPs and creating gene-level summaries, is gene-based MDR [55]. For each gene, the best within-gene SNP interaction model is considered to be a gene-level binary predictor for the trait and serves as input to a second run of MDR to find the best gene-level interaction model.

In this study, we identify epistasis signals via GWAS data by creating SNP sets allocated to the same gene and endowing the SNP sets with a network structure. The network structure allows information to be diffused over the corresponding graph and summarizing the SNP sets with diffusion kernel PCs (for instance, the first such component for each gene). The derived gene summaries serve as input to gene-level interaction models. In what follows, we motivate the components of this workflow and show how elements may be customized to accommodate different application settings.

Several SNP-to-gene mapping strategies exist. To exemplify the analysis workflow, we chose the most commonly used mapping method based on genetic distance with the FUMA software. Adopting such a genomic proximity mapping requires making additional choices of the maximum allowable distance (f.i., taking the closest gene or genes within a number of kbps of the index SNP). Alternatively, SNPs may be mapped to genes in a functional way. One example is eQTL mapping. Depending on the mapping strategy, several useful SNPs may be eliminated from the analysis. On the other hand, different opportunities to define a graphical structure between the SNPs annotated to the same gene may emerge. For instance, with genomic proximity mapping the sequence of SNPs on the genome can be used (LinearNet). Network edges may also be defined on the basis of linkage disequilibrium patterns between SNPs (LDNet). These approaches have been investigated before in the context of Type II diabetes [56]. With eQTL functional mapping, SNPs mapped to the same gene may be connected to each other when they act as each other's modifier in an eQTL epistasis relationship. The latter would imply the creation of SNP-set modules that are not disease-trait informed, but that can be regarded as "functional modules".

The use of entropy measures in GWAS and epistasis research is not new. For instance [57] considered Rényi entropy based single locus and two-locus association testing. A few years later, entropy-based test statistics for gene-gene interaction studies were reviewed in [58]. This study highlights the wide diversity of such measures. It should be noted that entropy-related concepts may be used differently by different authors as is the case for "information gain" (for example: [59–61]). Also, entropy-based measures may capture joint multi-locus effects [61] or purely interactive effects (no influence of main effects) as is the case in [62]. Furthermore, most software tools producing entropy based estimators require complete data. For this reason, we included an additional imputation step in the analysis protocol. That is, for available SNPs in the data, missing genotypes were imputed via k-nearest neighbors. More elaborate imputation strategies based on haplotypes or linkage disequilibrium exist and are commonly used in GWAS context but were not considered in this pilot analysis workflow. Alternatively, apart from being useful in testing, entropy-based measures can also be used in screening as was done in earlier work of ours [59]. In our analysis pipeline, we computed bivariate synergies between SNPs, not between all SNPs as in [59] but only between those that were annotated to the same gene. Furthermore, as only a handful of entropy based estimators for association with a quantitative trait are available (see references in [58]), we chose to discretize our non-binary trait that had been adjusted for confounding variables. It led to within-gene networks of SNPs with edge weights induced by the adopted synergy measure.

We preferred to generate weighted within-gene networks rather than binary networks to avoid specifying a synergy threshold that may well need to be gene-dependent, and

to have more refined diffusion of information. The beauty of our implemented strategy over LDNet and LinearNet is that network edges contain phenotype informed information. Furthermore, this approach is not a classical screening step that would reduce the number of subsequent SNP-based epistasis tests, in which case additional adjustments would be needed to account for elevated Type I errors caused by dependent testing and screening analysis stages.

In our approach, inspired by [63], we employed kernel PCA on a “sandwich” kernel matrix which contains a diffusion kernel as “filling”. The dimensions of the “sandwich” kernel are determined by the available number of individuals in the study. In GWAIS we wish to have sufficiently large sample sizes in order to boost the power for epistasis detection. The downside of large data sets is that it imposes challenges when computing principal components. For instance, for the IBD consortium data we used in this study, with over 60,000 individuals, special measures had to be taken when computing the kernels. In particular, we adhered to parallel computing at each stage of matrix multiplication, and also worked on partitions with at least 500GB of memory.

The kernel PCs computed per gene reduce to classical PCs when no association between SNPs within a gene is used. Indeed, in that case,  $\beta = 0$  and the filling  $exp^{\beta L}$  in the “sandwich” kernel reduces to the identity matrix (first term in the Taylor expansion). Using the average of the  $exp^{\beta L}$  matrices retrieved from several  $\beta$  values is better than using a single fixed  $\beta$  value for every gene as it enables the structure of different genes to dictate what the final kernel matrix would be. An area for further research is to better tune the  $\beta$  values especially for studies with large sample sizes for which eigen decompositions tend to be computationally demanding in the R software. Although the number of kernel PCs can be chosen using cross-validation, we chose the first kernel PC as main representative for each gene, giving rise to a single score for each gene per individual.

Notably, unlike gene-based MDR, we are not limiting gene summaries to a single SNP-level epistasis model. Rather, in our analysis workflow we possibly use an entire network structure between SNPs allocated to the same gene to summarize the gene. As suggested before, our approach is flexible in that the network structure may use trait information or not. When a within-network structure is absent, the corresponding gene summary boils down to classical (first) principal component derived from the gene set. Using principal components to summarize SNP information within a gene has been used before in gene-level interaction testing and genomewide association settings [64]. In the latter reference, as an alternative, trait information is used while summarizing a SNP set via partial least squares. Whereas [64] the first components are taken as gene summaries, in [65] genes are summarized by principal components that explain at least 80% of the variation. In contrast, in [66], SNP sets mapped to a gene pair are summarized by a so-called Eigen-Epistasis component. It stands for the linear combination of all respective SNP-SNP interactions that is the most correlated with the phenotype. We did not compare our implemented workflow with aforementioned existing methods, as only gene-based MDR also uses within-gene interaction information to derive gene summaries and since (SNP-based) MDR, on which it relies, suffers from several drawbacks as outlined in [67].

Bayesian models have several advantages, perhaps one of the most apparent one is that they naturally accommodate the inclusion of prior biological knowledge about associations. Several classes of such models for epistasis detection exist, including the BEAM

model as reviewed and extended in [68]. These models were shown to have rather low computational complexities. Here, we used gene representative kernel PCs in conjunction with a novel semi-parametric Bayesian model [34], while making inferences about gene and gene-gene interaction effects via Posterior Inclusion Probabilities (PIP), rather than via  $p$  values. GWAIS  $p$  values need to be adjusted for a huge number of multiple tests that may exhibit complex dependency structures between them. This imposes unresolved challenges of potentially high false negative rates and at the same time false positive rates that may not be acceptable [69]. It should be noted though that the adoption of Bayesian methods do not necessarily avoid the need for multiple testing correction, as was pointed out in [70]. In either case, in the current workflow, we took a PIP threshold of zero meaning that any gene or gene-gene interaction with a PIP strictly larger than zero was considered to be of predictive value to the phenotype and was included in downstream analyses. By no means should PIPs be interpreted as measures of association strength. Another motivation to work within a Bayesian paradigm is that in our workflow, only a relatively small number of variables needed to be mined (theoretically, as many variables as there are genes). Often, the advantages of some classes of Bayesian models in epistasis research are downplayed by the necessity to first filter the data and to reduce its dimensionality. Working with gene summaries as we have defined them naturally deals with this issue.

The final step of the analysis workflow involved interpretation of findings. All epistasis results were visualized in a gene interaction network and analyzed using network theory. The network may be the direct result of inferred interactions, but may also be the result of consulting external resources with “interaction” information. One such resource is GeneMANIA. By entering genes that were analytically identified as putative gene-gene interaction and/or as putative main effect (via  $PIP > 0$ ), GeneMANIA will build an entire network around them. Alternatively, identified genes can be propagated on a molecular network such as inBio, STRING, as in [71]. This bigger context may highlight interesting genes that were not directly identified via our epistasis detection models. It may highlight novel disease gene clusters and shed additional light on disease-related biological mechanisms. Notably, several molecular interaction databases exist each of them having differential performance, for instance in retrieving relevant disease genes [71]. Hence, experimental validation of promising results remains inevitable but may not always be feasible or accepted without replication evidence. Unfortunately, currently, there is no consensus in what replication means or should mean in the context of GWAIS [72].

Our analysis workflow applied to IBD spotlighted several known IBD associated genes and identified several gene-gene interactions. In practice, 41% of the 49 genes highlighted by our approach ( $PIP > 0$ ) could be traced back to previous reports about associations with IBD (Crohn’s, Ulcerative Colitis). Additional work is needed to investigate indirect links with IBD phenotypes. Comparing networks derived from analytic main effects and epistasis modelling complements the picture. For instance, Figs. 5 and 6 underscored three genes, namely *MAP1LC3A*, *RGS14* and *CNFTR*. No association evidence between these genes and IBD could be found. Regardless, from a network point of

view these 3 genes are interesting and worthwhile to follow-up in an attempt to determine their potential role in IBD pathology.

All of the above shows that the trait-informed dimensionality reduction step in our novel epistasis detection analysis workflow enhances the detection of gene-gene interaction effects and can detect genes associated with the phenotype. It fosters novel think tank paths to spur medical innovations. Additional optimizations at multiple layers of the analysis protocol are possible (as discussed) and are believed to further enhance the performance of our approach.

## Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12859-022-04580-7>.

**Additional file 1. Table S1:** Within gene network properties.

**Additional file 2. Table S2:** Main effects from model.

**Additional file 3.** supplementary figures.

## Acknowledgements

Data collection and processing were supported by funds to the International IBD Genetics Consortium. AW, DR and KVS acknowledge the European Union's Horizon 2020 research and innovation programme under grant agreement No 860895 (TransSYS-h2020transys.eu). DD acknowledge the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 813533 (MLFPM-mlfpm.eu), and RF acknowledges FP7 People grant agreement No 316861 (MLPM-mlpm.eu). KVS and JO also wish to thank Walloon Excellence in Life Sciences and Biotechnology (WELBIO) for having financed the foundations for this work. Thanks to the entire BIO3 at the GIGA-R Medical Genomics Unit (<http://www.bio3.giga.ulg.ac.be>) for their contributions. Thanks to Nejc Nadižar for his IT technical support (<http://cfgbc.mf.uni-lj.si/>).

## Author's contributions

AW under supervision of KVS developed and performed the detailed data analyses. AW, MM, DR and KVS wrote the manuscript. RF and JO performed analytic pilot work and conceptualized the core of the methodological approach, under supervision of KVS. DD designed the data curation protocol and prepared the data for the purposes of this manuscript. All authors read and approved the final manuscript.

## Funding

This project has received funding from the European Union's FP7 PEOPLE funding scheme under grant agreement No 316861 (MLPM-mlpm.eu), and the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 813533 (MLFPM-mlfpm.eu) and No 860895 (TransSYS-h2020transys.eu).

## Availability of data and materials

Data on IBD can be accessed via the International IBD Genetics Consortium ([www.ibdgenetics.org](http://www.ibdgenetics.org)). For this project, data were obtained through a Memorandum of Understanding with a representative of the consortium from the University of Liège and KU Leuven. Any interested party can access the data through a similar procedure.

## Code availability

The code necessary to reproduce this article's results and analyses is available on GitHub at: <https://github.com/awalakra/kPCAepistasis>.

## Declarations

### Ethics approval and consent to participate

The data used in this study was provided by the International IBD Genetics Consortium ([www.ibdgenetics.org](http://www.ibdgenetics.org)), who has collected the necessary consents and ethical approvals for the involved cohorts. A description of participating cohorts is given in [73].

### Consent for publication

The authors consent publication of this article

### Competing interests

The authors declare that they have no competing interests.

### Author details

<sup>1</sup>BIO3 - Laboratory for Systems Genetics, GIGA-R Medical Genomics, University of Liège, Liège, Belgium. <sup>2</sup>Centre for Functional Genomics and Bio-Chips, Institute for Biochemistry and Molecular Genetics, Faculty of Medicine, University

of Ljubljana, Ljubljana, Slovenia. <sup>3</sup>Faculty of Computer and Information Science, University of Ljubljana, Ljubljana, Slovenia. <sup>4</sup>BIO3 - Laboratory for Systems Medicine, Department of Human Genetics, KU Leuven, Leuven, Belgium.

Received: 30 June 2021 Accepted: 18 January 2022

Published online: 01 February 2022

## References

- Bateson W. Facts limiting the theory of heredity. *Science*. 1907;26(672):649–60.
- Fisher RA. The correlation between relatives on the supposition of mendelian inheritance. *Earth Environ Sci Trans R Soc Edinb*. 1919;52(2):399–433.
- Wang X, Elston RC, Zhu X. The meaning of interaction. *Hum Heredity*. 2010;70(4):269–77.
- Van Steen K, Moore J. How to increase our belief in discovered statistical interactions via large-scale association studies? *Hum Genet*. 2019;138(4):293–305.
- Moore JH, Williams SM. Traversing the conceptual divide between biological and statistical epistasis: systems biology and a more modern synthesis. *Bioessays*. 2005;27(6):637–46.
- Cordell HJ. Epistasis: what it means, what it doesn't mean, and statistical methods to detect it in humans. *Hum Mol Genet*. 2002;11(20):2463–8.
- Phillips PC. Epistasis—the essential role of gene interactions in the structure and evolution of genetic systems. *Nat Rev Genet*. 2008;9(11):855–67.
- Van Steen K. Travelling the world of gene–gene interactions. *Brief Bioinform*. 2012;13(1):1–19.
- Wang J, Joshi T, Valliyodan B, Shi H, Liang Y, Nguyen HT, Zhang J, Xu D. A Bayesian model for detection of high-order interactions among genetic variants in genome-wide association studies. *BMC Genom*. 2015;16(1):1011.
- Hemani G, Shakhbazov K, Westra H-J, Esko T, Henders AK, McRae AF, Yang J, Gibson G, Martin NG, Metspalu A, et al. Detection and replication of epistasis influencing transcription in humans. *Nature*. 2014;508(7495):249–53.
- Pecanka J, Jonker MA, Bochdanovits Z, Van Der Vaart AW. A powerful and efficient two-stage method for detecting gene-to-gene interactions in GWAS. *Biostatistics*. 2017;18(3):477–94.
- Calle ML, Urrea Gales V, Malats i Riera N, Van Steen K et al. Mb-mdr: model-based multifactor dimensionality reduction for detecting interactions in high-dimensional genomic data. 2008.
- Bessonov K, Gusareva ES, Van Steen K. A cautionary note on the impact of protocol changes for genome-wide association snp × snp interaction studies: an example on ankylosing spondylitis. *Hum Genet*. 2015;134(7):761–73.
- Chang Y-C, Wu J-T, Hong M-Y, Tung Y-A, Hsieh P-H, Yee SW, Giacomini KM, Oyang Y-J, Chen C-Y. Genepi: gene-based epistasis discovery using machine learning. *BMC Bioinform*. 2020;21(1):1–13.
- Ellinghaus D, Jostins L, Spain SL, Cortes A, Bethune J, Han B, Park YR, Raychaudhuri S, Pouget JG, Hübenthal M, et al. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. *Nat Genet*. 2016;48(5):510–8.
- Watanabe K, Taskesen E, Van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. *Nat Commun*. 2017;8(1):1–11.
- Duroux D, Climente-González H, Wienbrandt L, Van Steen K. Network aggregation to enhance results derived from multiple analytics. In: IFIP international conference on artificial intelligence applications and innovations, 2020. Springer. p. 128–140.
- Gusareva ES, Van Steen K. Practical aspects of genome-wide association interaction analysis. *Hum Genet*. 2014;133(11):1343–58.
- Abegaz F, Van Lishout F, Mahachie John JM, Chiachoompu K, Bhardwaj A, Gusareva ES, Wei Z, Hakonarson H, Van Steen K, Consortium, I.I.G. Epistasis detection in genome-wide screening for complex human diseases in structured populations. *Syst Med*. 2019;2(1):19–27.
- Franzin A, Sambo F, Di Camillo B. bnstruct: an R package for Bayesian network structure learning in the presence of missing data. *Bioinformatics*. 2017;33(8):1250–2.
- R Core Team: R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria (2019). R Foundation for Statistical Computing. <https://www.R-project.org/>
- Meyer PE, Meyer MPE. Package 'infotheo'. R Packag. version 2009; 1.
- Dougherty J, Kohavi R, Sahami M. Supervised and unsupervised discretization of continuous features. In: Machine learning proceedings 1995. Elsevier; 1995. p. 194–202.
- Ignac TM, Skupin A, Sakhanenko NA, Galas DJ. Discovering pair-wise genetic interactions: an information theory-based approach. *PLoS ONE*. 2014;9(3):92310.
- Varadan V, Miller DM III, Anastassiou D. Computational inference of the molecular logic for synaptic connectivity in *C. elegans*. *Bioinformatics*. 2006;22(14):497–506.
- Hu T, Sinnott-Armstrong NA, Kiralis JW, Andrew AS, Karagas MR, Moore JH. Characterizing genetic interactions in human disease association studies using statistical epistasis networks. *BMC Bioinform*. 2011;12(1):1–13.
- Meyer PE, Lafitte F, Bontempi G. minet: Ar/bioconductor package for inferring large transcriptional networks using mutual information. *BMC Bioinform*. 2008;9(1):461.
- Peng H, Long F, Ding C. Feature selection based on mutual information criteria of max-dependency, max-relevance, and min-redundancy. *IEEE Trans Pattern Anal Mach Intell*. 2005;27(8):1226–38.
- Csardi G, Nepusz T, et al. The igraph software package for complex network research. *InterJournal Complex Syst*. 2006;1695(5):1–9.
- Csardi MG. Package 'igraph'. Last accessed. 2013;3(09):2013.
- Kondor RI, Lafferty J. Diffusion kernels on graphs and other discrete structures. In: Proceedings of the 19th international conference on machine learning, vol 2002; 2002. p. 315–22.



32. Smola AJ, Kondor R. Kernels and regularization on graphs. In: Learning theory and kernel machines. Springer; 2003. p. 144–158.
33. Qiu Y, Mei J, Guennebaud G, Niesen J. Rspecra: solvers for large scale eigenvalue and svd problems. R package version 0.12-0. 2016;405.
34. Antonelli J, Mazumdar M, Bellinger D, Christiani D, Wright R, Coull B, et al. Estimating the health effects of environmental mixtures using Bayesian semiparametric regression and sparsity inducing priors. *Ann Appl Stat*. 2020;14(1):257–75.
35. Lesaffre E, Lawson AB. Bayesian biostatistics. Hoboken: Wiley; 2012. p. 358.
36. van den Berg I, Fritz S, Boichard D. Qtl fine mapping with bayes c ( $\pi$ ): a simulation study. *Genet Sel Evol*. 2013;45(1):1–11.
37. Barbieri MM, Berger JO, et al. Optimal predictive model selection. *Ann Stat*. 2004;32(3):870–97.
38. Ly V, Fokoué E. Frequentist approximation of the bayesian posterior inclusion probability by stochastic subsampling. *J Adv Math Comput Sci*. 2016;1–22.
39. Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT, et al. The genemania prediction server: biological network integration for gene prioritization and predicting gene function. *Nucleic Acids Res*. 2010;38(suppl-2):214–20.
40. Li T, Wernersson R, Hansen RB, Horn H, Mercer J, Slodkowicz G, Workman CT, Rigina O, Rapacki K, Stærfeldt HH, et al. A scored human protein-protein interaction network to catalyze genomic interpretation. *Nat Methods*. 2017;14(1):61.
41. Sherman BT, Lempicki RA, et al. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc*. 2009;4(1):44.
42. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res*. 2009;37(1):1–13.
43. Piñero J, Bravo A, Queralt-Rosinach N, Gutiérrez-Sacristán A, Deu-Pons J, Centeno E, García-García J, Sanz F, Furlong LI. Disgenet: a comprehensive platform integrating information on human disease-associated genes and variants. *Nucleic Acids Res*. 2016;943.
44. Piñero J, Queralt-Rosinach N, Bravo A, Deu-Pons J, Bauer-Mehren A, Baron M, Sanz F, Furlong LI. Disgenet: a discovery platform for the dynamical exploration of human diseases and their genes. *Database*. 2015;2015.
45. Yoshioka A, Miyata H, Doki Y, Yamasaki M, Sohma I, Gotoh K, Takiguchi S, Fujiwara Y, Uchiyama Y, Monden M. Lc3, an autophagosome marker, is highly expressed in gastrointestinal cancers. *Int J Oncol*. 2008;33(3):461–8.
46. Giatromanolaki A, Koukourakis MI, Georgiou I, Kouroupi M, Sivridis E. Lc3a, Lc3b and beclin-1 expression in gastric cancer. *Anticancer Res*. 2018;38(12):6827–33.
47. Gregersen PK, Amos CI, Lee AT, Lu Y, Remmers EF, Kastner DL, Seldin MF, Criswell LA, Plenge RM, Holers VM, et al. Rel, encoding a member of the nf- $\kappa$ b family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. *Nat Genet*. 2009;41(7):820–3.
48. Sakai H, Ohuchida K, Mizumoto K, Cui L, Nakata K, Toma H, Nagai E, Tanaka M. Inhibition of p600 expression suppresses both invasiveness and anoikis resistance of gastric cancer. *Ann Surg Oncol*. 2011;18(7):2057–65.
49. Kalim AS, Liana E, Fauzi AR, Sirait DN, Afandy D, Kencana SMS, Purnomo E, Iskandar K, Makhmudi A, et al. Aberrant ubr4 expressions in hirschsprung disease patients. *BMC Pediatr*. 2019;19(1):493.
50. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JC, Chan FK, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. *Lancet*. 2017;390(10114):2769–78.
51. Niel C, Sinoquet C, Dina C, Rocheleau G. A survey about methods dedicated to epistasis detection. *Front Genet*. 2015;6:285.
52. Wright MN, Ziegler A, König IR. Do little interactions get lost in dark random forests? *BMC Bioinform*. 2016;17(1):145.
53. Duroux D, Climente-González H, Azencott C-A, Van Steen K. Interpretable network-guided epistasis detection. *bioRxiv* 2020.
54. Behr M, Kumbier K, Cordova-Palomera A, Aguirre M, Ashley E, Butte A, Arnaout R, Brown JB, Preist J, Yu B. Learning epistatic polygenic phenotypes with Boolean interactions. *bioRxiv* 2020.
55. Oh S, Lee J, Kwon M-S, Weir B, Ha K, Park T. A novel method to identify high order gene-gene interactions in genome-wide association studies: gene-based MDR. *BMC Bioinform*. 2012;13:1–9 (**BioMed Central**).
56. Fouladi R. From statistical to biological interactions towards an omics-integrated MB-MDR framework. Ph.D. thesis, Université de Liège, Liège, Belgique 2018.
57. De Andrade M, Wang X. Entropy based genetic association tests and gene-gene interaction tests. *Stat Appl Genet Mol Biol*. 2011;10(1):38.
58. Ferrario PG, König IR. Transferring entropy to the realm of GxG interactions. *Brief Bioinform*. 2018;19(1):136–47.
59. Calle ML, Urrea V, Vellalta G, Malats N, Steen K. Improving strategies for detecting genetic patterns of disease susceptibility in association studies. *Stat Med*. 2008;27(30):6532–46.
60. Fan R, Zhong M, Wang S, Zhang Y, Andrew A, Karagas M, Chen H, Amos C, Xiong M, Moore J. Entropy-based information gain approaches to detect and to characterize gene-gene and gene-environment interactions/correlations of complex diseases. *Genet Epidemiol*. 2011;35(7):706–21.
61. Kwon M-S, Park M, Park T. Igent: efficient entropy based algorithm for genome-wide gene-gene interaction analysis. *BMC Med Genom*. 2014;7(S1):6.
62. Malten J, König IR. Modified entropy-based procedure detects gene-gene-interactions in unconventional genetic models. *BMC Med Genom*. 2020;13:1–12.
63. Fouladi R, Bessonov K, Van Lishout F, Van Steen K. Model-based multifactor dimensionality reduction for rare variant association analysis. *Hum Heredity*. 2015;79(3–4):157–67.
64. Wang T, Ho G, Ye K, Strickler H, Elston RC. A partial least-square approach for modeling gene-gene and gene-environment interactions when multiple markers are genotyped. *Genet Epidemiol Off Publ Int Genet Epidemiol Soc*. 2009;33(1):6–15.

65. Li J, Tang R, Biernacka JM, De Andrade M. Identification of gene–gene interaction using principal components. *BMC Proc.* 2009;3:1–6 (**BioMed Central**).
66. Stanislas V, Dalmasso C, Ambroise C. Eigen-epistasis for detecting gene–gene interactions. *BMC Bioinform.* 2017;18(1):1–14.
67. Cattaert T, Calle ML, Dudek SM, John JMM, van Lishout F, Urrea V, Ritchie MD, van Steen K. A detailed view on model-based multifactor dimensionality reduction for detecting gene–gene interactions in case–control data in the absence and presence of noise. *Ann Hum Genet.* 2011;75(1):78.
68. Zhang Y, Jiang B, Zhu J, Liu JS. Bayesian models for detecting epistatic interactions from genetic data. *Ann Hum Genet.* 2011;75(1):183–93.
69. Pineda S, Sirota M. Determining significance in the new era for p values. *J Pediatr Gastroenterol Nutr.* 2018;67(5):547–8.
70. Sjölander A, Vansteelandt S. Frequentist versus Bayesian approaches to multiple testing. *Eur J Epidemiol.* 2019;34(9):809–21.
71. Huang JK, Carlin DE, Yu MK, Zhang W, Kreisberg JF, Tamayo P, Ideker T. Systematic evaluation of molecular networks for discovery of disease genes. *Cell Syst.* 2018;6(4):484–95.
72. Ritchie MD, Van Steen K. The search for gene–gene interactions in genome-wide association studies: challenges in abundance of methods, practical considerations, and biological interpretation. *Ann Transl Med.* 2018;6(8):157.
73. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. *Nature.* 2012;491(7422):119–24.

### **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

